NOTICIAS

Últimas Noticias

ICYMI: Rubio Joins Kudlow

U.S. Senator Marco Rubio (R-FL) joined Kudlow to discuss terrorists crossing the southern border, the conservative case for industrial policy, and more. Watch the full interview on YouTube and Rumble. On the senator’s recent op-ed about terrorists crossing the...

leer más

Rubio, Bennet Applaud House Passage of RACE for Children Act

Jul 12, 2017 | Comunicados de Prensa

Washington, D.C. – U.S. Senators Marco Rubio (R-FL) and Michael Bennet (D-CO), along with Senators Cory Gardner (R-CO) and Chris Van Hollen (D-MD), today applauded the passage in the U.S. House of Representatives of the RACE for Children Act as part of the FDA User Fees reauthorization bill. 
 
In February, Senators Rubio, Bennet, Gardner, and Van Hollen introduced the Research to Accelerate Cures and Equity (RACE) for Children Act to support the development of innovative and promising cancer drugs for children.
 
“Today’s passage of the RACE for Children Act in the House is great news,” said Rubio. “We are one step closer to developing innovative and promising cancer drugs for children across the country who desperately need them. I urge my colleagues to support this bill when it comes before the Senate. It is crucial this legislation becomes law so that children with cancer have hope for a better future.”
 
“Today’s passage of the RACE for Children Act in the House is a significant step for children around the country who deserve lifesaving treatments,” said Bennet. “We should be able to tell parents with kids who are battling cancer that we’re doing everything we can to develop breakthrough drugs to treat their children. Today’s House vote brings us closer to that goal. We are thankful to Chairman Lamar Alexander for his leadership in supporting this legislation. And we look forward to the User Fees bill coming before the Senate.”
 
The bipartisan RACE for Children Act, first introduced in the 114th Congress, would update the Pediatric Research Equity Act (PREA) to reflect the latest advances in cancer drugs. Congress enacted PREA in 2003 to address the scarcity of information about how to treat children with drugs developed and approved for adults. Although PREA has resulted in new information on how to treat children for a multitude of drugs over the years, there are still limited pediatric studies for cancer drugs. This bill would update PREA by ensuring that the most innovative molecular-targeted drugs for cancer are also studied for children when appropriate. The bill also directs the Food and Drug Administration (FDA) to work with manufacturers to speed up studies for drugs that treat other serious or life-threatening diseases in children. 

Numerous pediatric oncology groups support the RACE for Children Act, including St. Jude Children’s Research Hospital, St. Baldrick’s Foundation, Live Like Bella Childhood Cancer Foundation, Nemours Children’s Health System, Arnold Palmer Hospital, Moffitt Cancer Center, Kids v. Cancer, the Children’s Hospital Colorado, Children’s Hospital of Philadelphia, Children’s Medical Center of Dallas, Dana-Farber Cancer Institute, Duke University Medical Center, Harvard Medical School, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, NYU Langone Medical Center, Texas Children’s Hospital, the Alliance for Childhood Cancer, the American Society of Clinical Oncology, and the American Cancer Society Cancer Action Network.